TP53 and ovarian carcinoma: Ultimately, it inhibits the EMT process and the malignant phenotype of tumor cells.Based on these findings, intervention strategies targeting TOP2A or combining with TP53 agonists provide a potential direction for the treatment of cisplatin-resistant ovarian cancer and the improvement of patient prognosis.